Who Generates More Revenue? Pfizer Inc. or TG Therapeutics, Inc.

Revenue Showdown: Pfizer Inc. vs. TG Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Pfizer Inc. has consistently outperformed TG Therapeutics, Inc. in terms of revenue. From 2014 to 2023, Pfizer's revenue surged by approximately 100%, peaking in 2022 with a staggering 100 billion dollars, largely driven by its COVID-19 vaccine success. In contrast, TG Therapeutics, Inc., a smaller biotech firm, saw its revenue grow from a modest 152,000 dollars in 2014 to over 233 million dollars in 2023, marking a significant growth trajectory albeit on a smaller scale. This comparison highlights the vast difference in scale between established pharmaceutical giants and emerging biotech companies, offering insights into their respective market strategies and growth potential.